G-protein-coupled receptors (GPCRs) are integral membrane proteins that have an essential role in human physiology, yet the molecular processes through which they bind to their endogenous agonists and activate effector proteins remain poorly understood. So far, it has not been possible to capture an active-state GPCR bound to its native neurotransmitter. Crystal structures of agonist-bound GPCRs have relied on the use of either exceptionally high-affinity agonists 1,2 or receptor stabilization by mutagenesis [3] [4] [5] . Many natural agonists such as adrenaline, which activates the b 2 -adrenoceptor (b 2 AR), bind with relatively low affinity, and they are often chemically unstable. Using directed evolution, we engineered a high-affinity camelid antibody fragment that stabilizes the active state of the b 2 AR, and used this to obtain crystal structures of the activated receptor bound to multiple ligands. Here we present structures of the active-state human b 2 AR bound to three chemically distinct agonists: the ultrahigh-affinity agonist BI167107, the high-affinity catecholamine agonist hydroxybenzyl isoproterenol, and the low-affinityendogenousagonistadrenaline. The crystal structures reveal a highly conserved overall ligand recognition and activation mode despite diverse ligand chemical structures and affinities that range from 100 nM to 80 pM. Overall, the adrenaline-bound receptor structure is similar to the others, but it has substantial rearrangements in extracellular loop three and the extracellular tip of transmembrane helix 6. These structures also reveal a watermediated hydrogen bond between two conserved tyrosines, which appears to stabilize the active state of the b 2 AR and related GPCRs.
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G-protein-coupled receptors (GPCRs) are integral membrane proteins that have an essential role in human physiology, yet the molecular processes through which they bind to their endogenous agonists and activate effector proteins remain poorly understood. So far, it has not been possible to capture an active-state GPCR bound to its native neurotransmitter. Crystal structures of agonist-bound GPCRs have relied on the use of either exceptionally high-affinity agonists 1, 2 or receptor stabilization by mutagenesis [3] [4] [5] . Many natural agonists such as adrenaline, which activates the b 2 -adrenoceptor (b 2 AR), bind with relatively low affinity, and they are often chemically unstable. Using directed evolution, we engineered a high-affinity camelid antibody fragment that stabilizes the active state of the b 2 AR, and used this to obtain crystal structures of the activated receptor bound to multiple ligands. Here we present structures of the active-state human b 2 AR bound to three chemically distinct agonists: the ultrahigh-affinity agonist BI167107, the high-affinity catecholamine agonist hydroxybenzyl isoproterenol, and the low-affinityendogenousagonistadrenaline. The crystal structures reveal a highly conserved overall ligand recognition and activation mode despite diverse ligand chemical structures and affinities that range from 100 nM to 80 pM. Overall, the adrenaline-bound receptor structure is similar to the others, but it has substantial rearrangements in extracellular loop three and the extracellular tip of transmembrane helix 6. These structures also reveal a watermediated hydrogen bond between two conserved tyrosines, which appears to stabilize the active state of the b 2 AR and related GPCRs.
GPCRs relay extracellular signals across a cell membrane by means of a conformational change after the binding of an extracellular agonist. GPCR activation by endogenous agonists remains poorly understood owing to the paucity of active receptor structures that have been elucidated in complex with agonists. Although a number of GPCRs have been crystallized in recent years, only the b 2 AR and rhodopsin have been crystallized in fully active states 1, 6 , and in both cases structures are available only for complexes with a single agonist. Owing to the conformational plasticity and biochemical instability of agonistbound receptors 7 , the few agonist-bound structures of GPCRs solved thus far have relied on the use of covalent 1 or extremely high-affinity agonists 2 , crystallographic chaperones to trap active states (a G protein 8 or antibody fragment 9 ), or thermostabilizing mutations 3 . The last approach has only yielded structures of agonist-occupied receptor in partially active 3, 4 or inactive 5 conformations. To understand better how diverse agonists can activate a single receptor, we developed a strategy for stabilizing active-state structures of the b 2 AR bound to low-affinity agonists including the natural agonist adrenaline. Here, we describe the directed evolution of Nb80, a conformationally selective single-domain camelid antibody fragment (nanobody) that was used to obtain the first active-state structure of the b 2 AR 9 . Comparison with the structure of the b 2 AR in complex with the G protein G s confirmed that Nb80 stabilizes a physiologically relevant active state 8 . However, the b 2 AR-Nb80 structure was of modest resolution (3.5 Å ) and crystals could only be obtained with the high-affinity agonist BI167107; crystallization trials with catecholamine agonists were unsuccessful despite extensive screening. We reasoned that improving the affinity of Nb80 for agonist-bound b 2 AR would decrease receptor conformational heterogeneity and enable crystallization of the receptor bound to low-affinity agonists. However, directed evolution of conformationally selective GPCR-binding proteins has never been described, probably owing to the challenges involved in biochemical manipulation of integral membrane proteins. We used yeast surface display together with a conformationally specific selection strategy to improve the binding affinity of Nb80 while maintaining its conformational selectivity. The resulting high-affinity variants retain their specificity for the active state of the receptor, which was characteristic of the original Nb80. Using the high-affinity variant Nb6B9, we determined a high-resolution (2.8 Å ) active-state structure of the b 2 AR bound to BI167107, and also determined the structures of the b 2 AR bound to two catechol-containing agonists: hydroxybenzyl isoproterenol (HBI) and adrenaline, an endogenous low-affinity agonist of the b 2 AR, at 3.1 Å and 3.2 Å resolution, respectively.
To assess the feasibility of engineering Nb80, we displayed Nb80 on the surface of the yeast strain EBY100 as an amino-terminal fusion to the yeast cell-wall protein Aga2p (Fig. 1a) . Yeast displaying Nb80 were stained with purified, detergent-solubilized, biotinylated b 2 AR after pre-incubation of receptor with the agonist BI167107 or the inverse agonist carazolol. Nb80-displaying yeast specifically bound to b 2 AR with an overwhelming preference for agonist-occupied receptor (Fig. 1b) , with a half-maximum effective concentration (EC 50 ) of 140 nM ( Supplementary Fig. 1a ). Next, we constructed a library of Nb80 mutants in which residues at the receptor-binding surface were randomized with conservative substitutions (Supplementary Fig. 2 ). The library was subjected to six rounds of selection (Fig. 1c) . First, the library was positively selected with decreasing concentrations of BI167107-bound b 2 AR. Before positive selection in rounds 2-5, the library was negatively selected against binding to inverse-agonistoccupied b 2 AR in order to remove variants that had lost conformational specificity. For the final round of selection, we enriched variants with the slowest dissociation rates. Receptor rebinding was blocked by the addition of a large excess of soluble Nb80 after the initial receptorbinding step (Supplementary Fig. 3 ). This selection strategy resulted in a progressive increase in binding affinity for agonist-occupied receptor without a similar increase in binding to inverse-agonist-occupied receptor (Fig. 1d) . Nanobody 6B9 (Nb6B9) was chosen from 23 variants screened from the final round of selection ( Supplementary Fig. 4 ) as it represented one of the highest-affinity binders tested, contained mutations that reached consensus among all sequenced clones, and was the most prevalent sequence observed. We expressed and purified Nb6B9 and Nb80, and then used surface plasmon resonance (SPR) to measure binding kinetics and affinities. Nb6B9 bound to BI167107-occupied b 2 AR with an affinity of 6.4 nM, a near tenfold improvement over Nb80 (Fig. 1e ). This increase in affinity resulted from a 13-fold reduction in the dissociation rate. Competition binding experiments revealed that the b 2 AR bound adrenaline with a high affinity in the presence of 100 nM Nb6B9, which is comparable to the affinity observed in the presence of the G protein G s (Fig. 1f) . Table 2 ). Data and error bars represent the mean 6 standard error of the mean from three experiments. 
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We used the lipidic mesophase method 10 to crystallize complexes of Nb6B9 with b 2 AR bound to three different ligands, shown in Fig. 2a . Crystals grown with b 2 AR bound to the high-affinity agonist BI167107 showed strong diffraction, and a structure was obtained to 2.8 Å resolution (Supplementary Table 1 ). This represents a significant improvement over the previous 3.5 Å structure of b 2 AR bound to the same ligand 9 . This higher-resolution structure showed few differences from the Nb80 complex structure ( Supplementary Fig. 5 ). Mutations in Nb6B9 appear to increase shape complementarity to active b 2 AR (Supplementary Fig. 6 ). Many water molecules were clearly resolved for the first time, particularly in the extracellular region of the receptor (Fig. 2b, c) . On the intracellular side of the receptor, a water molecule was found to mediate a hydrogen bond between Tyr 326 7.53 of the NPxxY motif and the highly conserved Tyr 219 5.58 on the intracellular side of transmembrane helix 5 (TM5), similar to a water seen in a recent structure of metarhodopsin II 11 . Electron density suggestive of a water molecule was also seen in HBI-and adrenaline-bound b 2 AR structures, despite their slightly lower resolution. The water-mediated hydrogen bond between Tyr 219 5.58 and Tyr 326 7.53 is possible only in the active conformation of the receptor (Fig. 2c) , and the observed water-mediated hydrogen bond may therefore contribute to active state stability in the b 2 AR and other GPCRs, serving as an active-state counterpart to the 'ionic lock' that stabilizes the inactive state 12 . In support of this notion, mutation of the corresponding Tyr 223 5.58 to phenylalanine in rhodopsin decreases the stability of the meta II state 13 and greatly reduces activation of transducin 14 . Moreover, mutation of Tyr 227 5.58 to alanine resulted in the largest increase in thermostability for the inactive-state thermostabilized b 1 AR 15 . Although BI167107 exhibits many features typical of b 2 AR agonists, it lacks the catechol moiety of the endogenous agonists adrenaline and noradrenaline. Hence, it is conceivable that these agonists stabilize a different conformation of the activated receptor-binding pocket. To assess this possibility, we pursued crystallographic studies of complexes of Nb6B9 with b 2 AR bound to the low-affinity endogenous agonist adrenaline and the high-affinity catecholamine agonist HBI. In each case, crystals could be grown in nearly identical conditions to those for the BI167107 complex, with clear electron density to identify the position and orientation of each ligand ( Supplementary Fig. 7) .
Despite the chemical diversity of these ligands, the structures of b 2 AR bound to the catecholamine agonists and to BI167107 have very similar overall structures (Fig. 3a, b) . A notable exception is a shift in the position of Asn 293 6.55 , which was previously determined to hydrogen bond with the amide carbonyl on the head group of BI167107. The smaller catechol ring of adrenaline and HBI precludes hydrogen 
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bonding with Asn 293 6.55 in the receptor conformation observed in the BI167107-bound structure. To maintain the corresponding hydrogen bond between Asn 293 and the meta hydroxyl moiety on the catechol ring, the receptor undergoes a 1.2 Å shift in the extracellular side of TM6, which bends towards the ligand (Fig. 3c) . This shift alters the hydrogen-bonding network in this region and thereby causes a change in the conformation of His 296 6.58 . For adrenaline-bound b 2 AR, the TM6 conformational change is further propagated towards the extracellular side of the receptor, leading to a conformational rearrangement in extracellular loop 3 (ECL3; Fig. 3d ). This change also alters the extracellular surface of the receptor, with adrenaline-bound b 2 AR having a contracted extracellular vestibule (Supplementary Fig. 8 ).
The relatively subtle differences in receptor conformation observed for the different co-crystallized agonists suggest that the activation mechanism of the b 2 AR is highly similar for all agonists. Much like BI167107, the catechol head groups of adrenaline and HBI engage b 2 AR residues previously characterized to be important for agonist binding and receptor activation (Supplementary Fig. 9 ). Consistent with prior mutagenesis studies, Ser 203
5.42 and Ser 207 5.46 make hydrogen bonds with the catecholamine phenoxy moeities 16 ( Fig. 3a-c) , and the conformation of these residues is nearly identical to that observed for the BI167107 head group. Ser 204 5.43 , which was previously thought to contact the para-hydroxy group of the catecholamine directly 16, 17 , engages the catecholamine head group indirectly in an extended polar network with Tyr 308 7.35 and Asn 293 6.55 . However, unlike BI167107-bound b 2 AR, this polar interaction network is extended by inclusion of His 296 6.58 in the catecholamine-bound receptor, suggesting that conformational rearrangement of His 296 6 .58 may stabilize the slightly smaller orthosteric binding pocket observed for catecholamine agonists. The agonist-induced rearrangements in the central portion of the transmembrane segments and intracellular surface are virtually identical in all three agonist-bound structures ( Fig. 3b and Supplementary  Fig. 10 ). Structures of b 2 AR bound to BI167107 and the catecholamine agonists all show very similar activation-related changes in the residues that connect the orthosteric ligand-binding pocket to the intracellular surface, suggesting that the mechanism for allosteric coupling between the orthosteric binding site and the G-protein-coupling domain is probably a conserved feature of b 2 AR activation. Therefore, different 
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agonists stabilize the same conformational rearrangements in the receptor through different chemical interactions.
In contrast to the marked similarity in receptor conformation for all three agonists crystallized here, far more substantial conformational differences are seen relative to a previously reported structure of the thermostabilized turkey b 1 -adrenoceptor (b 1 AR) bound to the catecholamine agonist isoproterenol 5 . Probably due to the thermostabilization procedure, the overall receptor conformation of isoprenalinebound b 1 AR closely resembles that of the antagonist-bound, inactive b 1 AR 18 , as well as that of covalent-agonist-bound, inactive b 2 AR 1 ( Supplementary Fig. 11 ). Thus, a comparison of the structural changes between inactive b 1 AR and active b 2 AR, each bound to catecholamines, offers new insight into how agonists bind adrenoceptors both in the low-affinity state and the high-affinity, G-protein-coupled state. Within the binding pocket, isoprenaline makes a hydrogen bond with Ser 211 5.42 and the b-hydroxylamine moiety engages conserved residues Asp 3.32 and Asn 7.39 in a very similar manner to the active-state structures (Fig. 4a, b) . Similar interactions can occur in both active and inactive states, probably accounting for the fact that the b-hydroxylamine moiety is an important feature of both b-adrenoceptor agonists and antagonists/inverse agonists. However, the isoprenaline catechol head group engages a limited network of polar contacts in the inactive b 1 AR structure, whereas adrenaline bound to active b 2 AR engages an extensive polar network linking the orthosteric site to the extracellular loops (Fig. 4a) . As a consequence of structural changes stabilized by this polar network, the catechol head group of adrenaline is nearly completely enclosed within the orthosteric binding pocket of activated b 2 AR (Fig. 4c) . In comparison, isoprenaline bound to inactive b 1 AR is highly exposed to the extracellular solvent and is slightly displaced towards the extracellular side of the receptor (Fig. 4d) . Thus, in b-adrenoceptors, the combination of a more extensive polar network and a smaller binding pocket probably accounts for the enhanced agonist affinity seen in the presence of either G s or G protein mimetic nanobodies. Moreover, such differences between active and inactive structures highlight the importance of active-state GPCR crystal structures in understanding the structural basis for agonist activity.
In conclusion, the use of new approaches in combinatorial biology has led to the development of Nb6B9, an exceptionally high-affinity GPCR-stabilizing nanobody. This molecule exhibits enhanced affinity for b 2 AR relative to wild-type Nb80, and it enabled the crystallization of b 2 AR in complex with three different agonists with diverse chemical structures and a wide range of affinities. The use of such high-affinity crystallization chaperones may be generally useful in the determination of active-state structures of GPCRs bound to low-affinity agonists. The crystallographic studies presented here reveal subtle, ligand-specific differences in receptor conformation superimposed on the backdrop of an overall conserved agonist-binding mode and activation mechanism, offering new insight into how chemically diverse agonists can activate a single receptor.
METHODS SUMMARY
Nb80 was displayed on the surface of EBY100 yeast as an N-terminal fusion to Aga2p, and an affinity-maturation library was generated by assembly PCR. Yeast were stained with detergent-solubilized receptor, and selections were carried out using magnetic-activated cell sorting. For crystallography, the b 2 AR with an N-terminal T4 lysozyme (T4L) fusion was expressed in Sf9 insect cells and purified by ligandaffinity chromatography. Nb80 and Nb6B9 were expressed in the Escherichia coli periplasm and purified by Ni-NTA chromatography. For crystallization, T4L-b 2 AR was incubated with ligand, followed by the addition of excess Nb6B9 and purification by gel filtration. The purified complex was reconstituted into the lipidic cubic phase and crystallized. Diffraction data were collected at Advanced Photon Source GM/CA beamlines 23ID-B and 23ID-D, and the structures were solved by molecular replacement.
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METHODS b 2 AR expression and purification. Human b 2 AR bearing an N-terminal Flag epitope tag and truncated after residue 365 was expressed in Sf9 insect cells using the BestBac baculovirus system (Expression Systems). Cells were infected at a density of 4 3 10 6 cells ml
21
, then incubated for two days at 27 uC. Receptor was extracted as described previously 19 . Receptor was first purified by Flag affinity chromatography, then labelled with a tenfold molar excess of biotin-PEG 11 -maleimide (Thermo Scientific), which reacts with the endogenous residue Cys 265. After a 1 h incubation at room temperature (22 uC), unlabelled receptor was blocked with 2 mM iodoacetamide for 15 min and then purified by alprenolol sepharose chromatography to isolate only functional receptor. Alprenolol sepharose eluate was concentrated on Flag affinity resin, and then washed with ligandfree buffer for 30 min at room temperature to eliminate bound alprenolol. Detergent was gradually exchanged from dodecyl maltoside (DDM) to lauryl maltose neopentyl glycol (MNG) by washing in buffer containing decreasing amounts of DDM and MNG at a fixed concentration of 0.1% (w/w). Receptor was eluted, aliquoted, and frozen in 20% glycerol. Display and functional evaluation of Nb80 on yeast. Nb80 was cloned into the C-terminal Aga2 yeast-display vector pYAL 20 and transformed and displayed on yeast as previously described 21 . Induced yeast displaying Nb80 were washed with PBE buffer (phosphate buffered saline with 0.5 mM EDTA and 0.5% BSA) supplemented with 0.02% MNG detergent (PBEM buffer) and stained with varying concentrations of biotinylated receptor bound to either BI167107 or carazolol for 1 h at 4 uC. The yeast were then washed with PBEM buffer and stained with Alexa-647-conjugated streptavidin for 15 min at 4 uC. Mean cell fluorescence was measured using the FL-4 channel of an Accuri C6 flow cytometer. Affinity maturation of Nb80. The affinity maturation library was prepared by assembly PCR with oligonucleotide primers (Supplementary Table 3) containing degenerate codons at 15 distinct positions (Supplementary Fig. 2 ). The PCR product was further amplified with primers containing 50 base pairs of homology to pYal. Mutagenic nanobody DNA and linearized pYAL vector were co-electroporated into EBY100 yeast to yield a library of 0. Rounds 2-6 were selected in a similar manner, with the following modifications. Before positive selection with agonist-occupied b 2 AR, negative selection with antagonist-bound receptor was performed to select for clones that maintained a preference for the active state of the b 2 AR. Briefly, 1.0 3 10 8 yeast were washed with PBEM buffer and resuspended in 500 ml PBEM buffer containing 1 mM biotinylated b 2 AR bound to carazolol. Yeast were incubated at 4 uC for 1 h, then labelled with Alexa-647-or PE-conjugated streptavidin, and magnetically labelled with 50 ml of the respective anti-fluorophore microbeads (Miltenyi) in 450 ml PBEM buffer. Magnetically labelled yeast were applied to an LS column and the depleted flow-through was collected for subsequent positive selection. In this manner, yeast clones binding the 'inactive', antagonist-occupied receptor were discarded. Positive selections on 'active', agonist-occupied receptor were performed as for round 1, but in a staining volume of 500 ml and with successively decreasing concentrations of BI167107-bound b 2 AR: 200 nM receptor for rounds 2 and 3, 20 nM receptor for round 4, and 1 nM receptor for round 5. For round 6, positive selection was performed by a kinetic selection strategy to select for clones with the slowest off-rates ( Supplementary Fig. 3 ). Briefly, yeast were stained with 200 nM biotinylated BI167107-bound b 2 AR for 1 h, washed with PBEM, and then resuspended in 500 ml PBEM containing 15 mM Nb80. The cells were incubated at 25 uC for 155 min, after which they were washed with ice-cold PBEM and stained with fluorescent streptavidin. Enrichment with magnetic separation for rounds 2-6 was performed as for round 1, but with 50 ml antifluorophore magnetic microbeads with 450 ml PBEM buffer. After round 6, postsorted yeast were plated onto SDCAA-agar plates, colonies were picked and cultured in liquid SDCAA medium, and the plasmids encoding the nanobodies were isolated with a ZymoPrep Yeast Plasmid Miniprep II kit (Zymo Research) and sequenced. Expression and characterization of Nb80 and Nb6B9. Nanobodies were cloned into the periplasmic expression vector pET26b, containing an N-terminal signal sequence and a C-terminal 83 histidine tag, and transformed into BL21(DE3) Rosetta2 Escherichia coli (Novagen). Cells were induced in Terrific Broth at an OD 600 nm of 0.8 with 1 mM IPTG and incubated with shaking at 22 uC for 24 h. Periplasmic protein was obtained by osmotic shock and the nanobodies were purified using nickel-nitrilotriacetic acid (Ni-NTA) chromatography 9 . For crystallography, Nb6B9 was digested overnight with 1:50 (w/w) carboxypeptidase A (Sigma) to remove the His tag, then purified by size-exclusion chromatography over a Sephadex S200 size-exclusion column.
SPR experiments were conducted with a Biacore T100 at 25 uC. Protein concentrations were determined by 280 nm absorbance with a Nanodrop2000 spectrometer (Thermo Scientific). Biotinylated BI167107-bound b 2 AR was immobilized on an SA sensorchip (GE) at a relative unit maximum (R max ) of nanobody bindingof approximately 40 RU. Biotinylated tiotropium-bound M 2 muscarinic receptor was immobilized with an RU value matching that of the reference surface to control for nonspecific binding. Measurements were made using serial dilutions of Nb80 or Nb6B9 in HBSM (10 mM HEPES pH 7.4, 150 mM NaCl, 0.01% MNG) using single-cycle kinetics. All data were analysed with the Biacore T100 evaluation software version 2.0 with a 1:1 Langmuir binding model.
Radioligand-binding assays were performed using purified b 2 AR reconstituted into high-density lipoprotein particles comprised of apolipoprotein A1 and a 3:2 (mol:mol) mixture of POPC:POPG lipid 22 . Binding experiments with G protein were performed as previously described 8 . Binding reactions were 500 ml in volume, and contained 50 fmol functional receptor, 0.5 nM 3 H dihydroalprenolol ( 3 H-DHA), 100 mM NaCl, 20 mM HEPES pH 7.5, 0.1% bovine serum albumin, and ligands and nanobodies as indicated. Reactions were mixed, then incubated for 4 h at room temperature before filtration with a Brandel 48-well harvester onto a filter pre-treated with 0.1% polyethylenimine. Radioactivity was measured by liquid scintillation counting. All measurements were performed in triplicate, and are presented as means 6 standard error of the mean. Purification and crystallization of b 2 AR-Nb6B9 complexes. Human b 2 AR fused to an N-terminal T4 lysozyme 23 was expressed in Sf9 insect cells and purified as described earlier. After purification by alprenolol sepharose, the receptor was washed extensively with 30 mM of the low-affinity antagonist atenolol while bound to Flag affinity resin to fully displace alprenolol, then washed and eluted in buffer devoid of ligand to produce a homogeneously unliganded preparation. The receptor was then incubated for 30 min at room temperature with a stoichiometric excess of ligand (HBI or BI167107). A 1.3-fold molar excess of Nb6B9 was then added, and the sample was dialysed overnight into a buffer consisting of 100 mM sodium chloride, 20 mM HEPES pH 7.5, 0.01% lauryl maltose neopentyl glycol detergent, and 0.001% cholesteryl hemisuccinate. In each case, ligand was included in the dialysis buffer at 100 nM concentration or higher. The sample was then concentrated using a 50 kDa spin concentrator and purified over a Sephadex S200 size-exclusion column in the same buffer as for dialysis, and the b 2 AR-Nb6B9-ligand ternary complex was isolated. In the case of adrenaline, the low affinity and chemical instability of the ligand precluded overnight dialysis, so 100 mM adrenaline was added to receptor for 30 min at room temperature, then a 1.3-fold molar excess of Nb6B9 was added and the sample was incubated for 30 min at room temperature. After incubation, the sample was concentrated and immediately purified by size exclusion as described earlier.
After purification, samples were concentrated to A 280 nm 5 55 using a 50 kDa concentrator to minimize the detergent concentration in the final sample, then aliquoted into thin-walled PCR tubes at 8 ml per aliquot. Aliquots were flash frozen in liquid nitrogen and stored at 280 uC for crystallization trials. For crystallization, samples were thawed and reconstituted into lipidic cubic phase with a 1:1 mass:-mass ratio of lipid. The lipid stock consisted of a 10:1 mix by mass of 7.7 monoacylglycerol (provided by M. Caffrey) with cholesterol (Sigma). Samples were reconstituted by the two-syringe mixing method 10 and then dispensed into glass sandwich plates using a GryphonLCP robot (Art Robbins Instruments). In the case of the b 2 AR-adrenaline complex, 1 mM fresh adrenaline was mixed with receptor before reconstitution. Crystals were grown using 30 nl protein/lipid drops with 600 nl overlay solution, which consisted of 18-24% PEG400, 100 mM MES pH 6.2 to pH 6.7, and 40-100 mM ammonium phosphate dibasic. Crystals grew in 1-3 days, and were harvested and frozen in liquid nitrogen for data collection. Crystallographic data collection and refinement. X-ray diffraction data were collected at Advanced Photon Source GM/CA beamlines 23ID-B and 23ID-D. The best diffracting crystals were identified by rastering, and wedges of 1-10u were collected using a 10 mm beam with typically 2 s exposure, 0.6u oscillation, and no beam attenuation. Data collection statistics are summarized in Supplementary  Table 1 . Diffraction data were processed in HKL2000 24 , and the structure was solved using molecular replacement with the structures of active b 2 AR, Nb80 (PDB accession 3P0G), and T4 lysozyme (PDB accession 2RH1) used as search models in Phaser 25 . RESEARCH LETTER
